<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2748">
  <stage>Registered</stage>
  <submitdate>26/04/2010</submitdate>
  <approvaldate>26/04/2010</approvaldate>
  <nctid>NCT01111955</nctid>
  <trial_identification>
    <studytitle>Safety Study of BMS-823778 in Subjects With Type 2 Diabetes</studytitle>
    <scientifictitle>A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MB121-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-823778
Treatment: drugs - BMS-823778
Treatment: drugs - BMS-823778
Treatment: drugs - Placebo
Treatment: drugs - Metformin

Active Comparator: BMS-823778 (2 mg) - + metformin

Active Comparator: BMS-823778 (10 mg) - + metformin

Active Comparator: BMS-823778 (20 mg) - + metformin

Placebo Comparator: Placebo - + metformin


Treatment: drugs: BMS-823778
Capsules, Oral, 2 mg, once daily, 28 days

Treatment: drugs: BMS-823778
Capsules, Oral, 10 mg, once daily, 28 days

Treatment: drugs: BMS-823778
Capsules, Oral, 20 mg, once daily, 28 days

Treatment: drugs: Placebo
Capsules, Oral, 0 mg, once daily, 28 days

Treatment: drugs: Metformin
Capsules, Oral, = 1500 mg, once daily, 28 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lowering of fasting plasma glucose (FPG) throughout the study to see if there is a decrease from baseline</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (measuring trough concentrations)</outcome>
      <timepoint>On days 7, 14 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics (measuring daily glucose, glucose AUC, HbA1c, lipid profiles, HPA markers, free testosterone, and SHBG)</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes mellitus

          -  Drug naive or on stable metformin therapy

          -  HbA1c 7-10%

          -  FPG = 240mg/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of myocardial infarction, coronary angioplasty or bypass grafts, valvular
             disease or repair, unstable angina pectoris, transient ischemic attack, or
             cerebrovascular accidents within six months prior to entry into the study

          -  Congestive heart failure

          -  Active liver disease

          -  Impaired renal function

          -  Hepatitis C, B and HIV

        This list is not inclusive; additional information is provided in the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>62</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Blacktown</hospital>
    <hospital>Local Institution - Box Hill</hospital>
    <hospital>Local Institution - Freemantle</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>6959 - Freemantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects
      on fasting plasma glucose (FPG).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01111955</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>